Stereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC)

Background: Management of Non-Small Cell Lung Cancer (NSCLC) patients with oligoprogression remains controversial. There is limited data to support the strategy of Stereotactic Ablative Radiotherapy (SABR) targeting the oligoprogressive disease in combination with ongoing systemic treatment. We aim...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Houda Bahig, Marion Tonneau, Normand Blais, Philip Wong, Edith Filion, Marie-Pierre Campeau, Toni Vu, Afnan Al-Saleh, Mustapha Tehfé, Marie Florescu, David Roberge, Laura Masucci, Corentin Richard, Cynthia Menard, Bertrand Routy
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Elsevier 2022-03-01
Цуврал:	Clinical and Translational Radiation Oncology
Нөхцлүүд:	Stereotactic body radiation therapy Non-Small Cell Lung Cancer Oligoprogression
Онлайн хандалт:	http://www.sciencedirect.com/science/article/pii/S2405630821001075
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!